Keyword: UC San Diego School of Medicine
UCSD researchers have developed a small molecule that weakens the virulent H3N2 strain of flu by exploiting a flaw in the mechanism the virus uses to replicate.
California researchers have gained insight into how a 30-year-old asthma drug called amlexanox helps burn calories—and it all ties into inflammation.
The past week's research news included developments in pediatric brain tumors, asthma and KRAS-mutant cancers.
Researchers are investigating a potentially useful role for Zika virus: treating glioblastoma.
An existing drug that boosts the production of vital immune cells could enhance both cancer immunotherapy and vaccine development.
Researchers have used a new version of CRISPR to fix problems in RNA rather than to edit DNA, a promising step for a group of diseases that have no cure.
UCSD scientists are repurposing the anti-inflammatory drug amlexanox to treat Type 2 diabetes.
UC San Diego scientists isolated “good bacteria” found on human skin and transplanted it to patients with eczema, finding that the treatment significantly cut down the amount of Staphylococcus aureus on their skin.
Neurodegenerative diseases like Huntington’s (HD) have lacked effective therapy, in part due to the difficulty in recapitulating the disease in a laboratory setting. Now a team of scientists has created a new model of HD and in doing so, discovered a protein subunit that may reverse the disease model.
Current heart failure therapy is limited by serious side effects. Researchers have now designed a computational approach to characterize protein structures that are targets for heart failure drugs. The results may lead to better drug development: compounds that can subtly fine-tune the heart, without the side effects.